[{"id":"110cd83b-a31c-4b26-8b05-9ad93be67a86","acronym":"","url":"https://clinicaltrials.gov/study/NCT04530565","created_at":"2021-01-18T21:41:29.599Z","updated_at":"2025-02-25T14:07:51.985Z","phase":"Phase 3","brief_title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","source_id_and_acronym":"NCT04530565","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ABL1 T315I","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL1 T315I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • dexamethasone • mesna • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-19"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"984a9572-0002-4941-9116-d4a0af76671f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05268003","created_at":"2022-03-07T18:53:49.340Z","updated_at":"2025-02-25T15:27:17.213Z","phase":"Phase 2","brief_title":"A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05268003","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/07/2022","start_date":" 06/07/2022","primary_txt":" Primary completion: 10/05/2026","primary_completion_date":" 10/05/2026","study_txt":" Completion: 10/05/2026","study_completion_date":" 10/05/2026","last_update_posted":"2025-02-10"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"770b6fe5-e7bb-4e08-b58f-bc15ae4f95a0","acronym":"NCI-2018-01078","url":"https://clinicaltrials.gov/study/NCT03263572","created_at":"2021-06-08T16:52:54.067Z","updated_at":"2025-02-25T14:50:41.961Z","phase":"Phase 2","brief_title":"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03263572 - NCI-2018-01078","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • Blincyto (blinatumomab) • methotrexate • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/29/2017","start_date":" 11/29/2017","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-12-10"},{"id":"67208ab2-da0d-429c-a27e-8240b35e734d","acronym":"ASC4TARGET","url":"https://clinicaltrials.gov/study/NCT06514534","created_at":"2025-02-26T09:29:56.710Z","updated_at":"2025-02-26T09:29:56.710Z","phase":"Phase 2","brief_title":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","source_id_and_acronym":"NCT06514534 - ASC4TARGET","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib) • Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/02/2024","start_date":" 12/02/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-07-23"},{"id":"a27b7cf2-f99d-42a1-97ab-640fcfb897fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01746836","created_at":"2021-01-18T07:39:23.997Z","updated_at":"2024-07-02T16:34:59.088Z","phase":"Phase 2","brief_title":"Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib","source_id_and_acronym":"NCT01746836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCR","pipe":"","alterations":" ","tags":["BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • Iclusig (ponatinib) • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/17/2013","start_date":" 01/17/2013","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-06-04"},{"id":"9cd3b684-d4e0-46a5-9cce-50d0019b2e7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01424982","created_at":"2021-06-14T08:53:14.488Z","updated_at":"2024-07-02T16:35:00.822Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT01424982","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Truxima (rituximab-abbs) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 10/05/2011","start_date":" 10/05/2011","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-05-27"},{"id":"9870d7f2-3f5a-43b5-abfd-5950b19ba180","acronym":"GMALL-EVOLVE","url":"https://clinicaltrials.gov/study/NCT06061094","created_at":"2023-09-29T19:11:18.358Z","updated_at":"2024-07-02T16:35:05.904Z","phase":"Phase 2","brief_title":"Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT","source_id_and_acronym":"NCT06061094 - GMALL-EVOLVE","lead_sponsor":"Goethe University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Iclusig (ponatinib) • Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2024-05-06"},{"id":"3a37bc3c-8cd8-4398-97d2-6d24383dcff4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04188405","created_at":"2021-01-18T20:24:56.671Z","updated_at":"2024-07-02T16:35:06.506Z","phase":"Phase 2","brief_title":"Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT04188405","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["ABL1 • BCR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/17/2020","start_date":" 05/17/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-02"},{"id":"b0a0dfce-1fec-4075-85ab-ace8d7ed1db4","acronym":"NCI-2018-01100","url":"https://clinicaltrials.gov/study/NCT03576547","created_at":"2021-01-18T17:35:49.383Z","updated_at":"2024-07-02T16:35:06.510Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT03576547 - NCI-2018-01100","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • BCL2","pipe":"","alterations":" ","tags":["ABL1 • BCR • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Iclusig (ponatinib) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/26/2018","start_date":" 06/26/2018","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-02"},{"id":"e6e36ef9-1a28-4271-9c2d-5395fb082dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT06390306","created_at":"2024-04-30T19:56:36.690Z","updated_at":"2024-07-02T16:35:06.686Z","phase":"","brief_title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","source_id_and_acronym":"NCT06390306","lead_sponsor":"Peking University People's Hospital","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Iclusig (ponatinib) • azacitidine • Nailike (olverembatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"0b066415-83ac-4fa2-948f-509a6c82d1fb","acronym":"TIPI","url":"https://clinicaltrials.gov/study/NCT04070443","created_at":"2022-04-24T09:01:28.160Z","updated_at":"2024-07-02T16:35:10.957Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","source_id_and_acronym":"NCT04070443 - TIPI","lead_sponsor":"Centre Leon Berard","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-04-08"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"fb46917b-b548-46ad-9a19-0529317c4698","acronym":"","url":"https://clinicaltrials.gov/study/NCT04845035","created_at":"2021-04-14T11:53:01.928Z","updated_at":"2025-02-25T14:59:48.077Z","phase":"Phase 2","brief_title":"Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04845035","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • Iclusig (ponatinib) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2024","start_date":" 01/01/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2024-02-22"},{"id":"542af943-09d2-4788-b665-53678488854f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05306301","created_at":"2022-04-01T21:53:27.389Z","updated_at":"2024-07-02T16:35:20.617Z","phase":"Phase 2","brief_title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","source_id_and_acronym":"NCT05306301","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/05/2022","start_date":" 10/05/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-02-07"},{"id":"ffd2ca60-82dd-404f-a539-82d708a898dd","acronym":"OPTIC","url":"https://clinicaltrials.gov/study/NCT02467270","created_at":"2021-01-18T11:52:32.635Z","updated_at":"2024-07-02T16:35:20.731Z","phase":"Phase 2","brief_title":"Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses","source_id_and_acronym":"NCT02467270 - OPTIC","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 283","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 04/14/2020","primary_completion_date":" 04/14/2020","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-06"},{"id":"450bad5e-226e-4803-b8bd-60c2c38937da","acronym":"Pona-CELL","url":"https://clinicaltrials.gov/study/NCT04554459","created_at":"2021-01-18T21:46:25.611Z","updated_at":"2024-07-02T16:35:23.461Z","phase":"Phase 2","brief_title":"Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL","source_id_and_acronym":"NCT04554459 - Pona-CELL","lead_sponsor":"Institute of Hematology and Blood Transfusion, Czech Republic","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Suspended","enrollment":" Enrollment 32","initiation":"Initiation: 02/16/2021","start_date":" 02/16/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-01-15"},{"id":"4d8663fb-c0ac-4fa9-9514-5c1ff4a7ba20","acronym":"ResToP","url":"https://clinicaltrials.gov/study/NCT04160546","created_at":"2021-01-18T20:17:33.899Z","updated_at":"2024-07-02T16:35:25.034Z","phase":"Phase 2","brief_title":"Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)","source_id_and_acronym":"NCT04160546 - ResToP","lead_sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib) • aspirin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/17/2020","start_date":" 01/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-28"},{"id":"ef97c411-7ef4-44d2-86ab-744d379519d4","acronym":"PHOENICS","url":"https://clinicaltrials.gov/study/NCT06119269","created_at":"2023-11-07T16:14:13.614Z","updated_at":"2024-07-02T16:35:30.366Z","phase":"","brief_title":"Ponatinib in CML Patients in Chronic Phase","source_id_and_acronym":"NCT06119269 - PHOENICS","lead_sponsor":"University of Pisa","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/02/2023","start_date":" 08/02/2023","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-06"},{"id":"f300739e-1f9e-42ac-8361-e1fbf968624a","acronym":"PhALLCON","url":"https://clinicaltrials.gov/study/NCT03589326","created_at":"2021-01-18T17:39:06.668Z","updated_at":"2024-07-02T16:35:31.409Z","phase":"Phase 3","brief_title":"A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03589326 - PhALLCON","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • Iclusig (ponatinib) • vincristine • prednisone • dexamethasone • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 10/04/2018","start_date":" 10/04/2018","primary_txt":" Primary completion: 08/12/2022","primary_completion_date":" 08/12/2022","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-10-27"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"df0a74df-c838-4261-8a1e-83694e9b917d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03704688","created_at":"2021-01-18T18:09:13.140Z","updated_at":"2024-07-02T16:35:36.357Z","phase":"Phase 1/2","brief_title":"Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03704688","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Iclusig (ponatinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/09/2018","start_date":" 10/09/2018","primary_txt":" Primary completion: 02/04/2022","primary_completion_date":" 02/04/2022","study_txt":" Completion: 02/04/2022","study_completion_date":" 02/04/2022","last_update_posted":"2023-09-21"},{"id":"fc5e8b29-6dcb-4531-a767-ace8038c4ef9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272998","created_at":"2021-01-18T10:41:33.356Z","updated_at":"2024-07-02T16:35:36.656Z","phase":"Phase 2","brief_title":"Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.","source_id_and_acronym":"NCT02272998","lead_sponsor":"Sameek Roychowdhury","biomarkers":" FLT3 • ABL1 • RET • PDGFRA • FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FLT3 • ABL1 • RET • PDGFRA • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/24/2015","start_date":" 02/24/2015","primary_txt":" Primary completion: 11/17/2022","primary_completion_date":" 11/17/2022","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-09-18"}]